Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Change in Receivables of -$623.18 for Q1 2026, up 66.02% year-on-year from -$375.36 in Q1 2025, and down 100.1% on a QoQ basis from $606548.3 in Q4 2025.
Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Receivables for 7 consecutive years, with -$623.18 the latest figure, recorded in Q1 2026.
- Quarterly Change in Receivables rose 66.02% year-over-year to -$623.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $662395.3 (up 301.33% YoY) and the FY2025 annual result came in at $606817.3, up 253.19% from the prior year.
- Change in Receivables declined to -$623.18 in Q1 2026 per MOLN's latest filing, from $606548.3 in the prior quarter.
- Over the last five years, Change in Receivables for MOLN reached as high as $26.2 million in Q4 2022 and fell as low as -$24.4 million in Q3 2022.
- A 5-year average of $1.5 million and a median of -$766.54 in 2023 frame the typical range for Change in Receivables.
- The largest YoY upside for Change in Receivables was 650.4% in 2022 against a maximum downside of 546.98% in 2022.
- Year by year, Change in Receivables stood at $26.2 million in 2022, then slumped by 104.01% to -$1.1 million in 2023, then jumped by 62.46% to -$394569.3 in 2024, then soared by 253.72% to $606548.3 in 2025, then slumped by 100.1% to -$623.18 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$623.18, $606548.3, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -623.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -623.18 |
| Mar 31, 2026 | -623.18 |
| Dec 31, 2025 | 606,548.35 |
| Dec 31, 2025 | 606,548.35 |
| Sep 30, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Mar 31, 2025 | -1,834.10 |
| Mar 31, 2025 | -1,834.10 |
| Dec 31, 2024 | -394,569.31 |
| Dec 31, 2024 | -394,569.31 |
| Sep 30, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | -1.54 Mn |
| Mar 31, 2024 | -1,364.51 |
| Mar 31, 2024 | -1,364.51 |
| Dec 31, 2023 | -1.05 Mn |
| Dec 31, 2023 | -1.05 Mn |